CoChat

High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing?

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Parenteral iron is given to patients in a variety of formulations, including two iron dextran products known as high- (HMW) or low- (LMW) molecular weight iron dextran. Despite more risk of adverse events, HMW iron dextran is sometimes substituted for LMW iron dextran without physician knowledge for reasons of cost. A recent decision by the Centers for Medicare and Medicaid Services (CMS) to re-merge J-codes for both iron dextrans may increase the unintended use of HMW iron dextran, resulting perhaps in more adverse drug events. Physicians who use parenteral iron should be aware of these practices and actively participate in formulary decisions regarding their substitution. Recently, in Tennessee, a physician ordered LMW iron dextran (INFeD, Watson, Morristown, NJ) in a patient for iron deficiency anemia when oral iron had been ineffective and tolerated poorly. The pharmacist substituted the less expensive HMW iron dextran (Dexferrum, American Regent, Shirley, NY). Anaphylaxis shortly after receiving a test dose of HMW iron dextran was followed by death. Despite at least nine publications demonstrating higher rates of adverse drug events with HMW iron dextran1–9 and with no publications showing contradictory results, HMW iron dextran continues to be substituted by individuals seemingly unaware of the various risk profiles among products for intravenous iron replacement. In one of these studies, the adverse event rate following administration of HMW iron dextran was 28%.5 The reported total absolute rates of adverse drug events with parenteral iron are 38 per million doses, with life-threatening adverse drug events per million of 11.3 for HMW iron dextran, 3.3 for LMW dextran, 0.9 for ferric gluconate, and 0.6 for iron sucrose.10 Even more worrisome is the ready substitution of HMW for LMW iron dextran because of cost, which is not a rare event. We have personally documented such occurrences where clinicians ordered LMW iron dextran and HMW iron dextran was substituted in its place. In four confirmed instances where anaphylaxis did not result in death, LMW iron dextran was subsequently administered uneventfully. By the early 1990s, intravenous iron was used routinely to synergize with erythropoiesis stimulating agents (ESAs) for the treatment of dialysis-associated anemia. LMW and HMW iron dextrans were the only products available throughout the 1990s. In 1997, LMW iron dextran became unavailable for several months, necessitating the use of HMW iron dextran in virtually all dialysis patients requiring intravenous iron to support erythropoiesis. During that period, there was an 1100% increase in adverse drug events reported to the Food and Drug Administration (FDA) following administration of iron dextran according to data obtained through the Freedom of Information Act (obtained by M.A.). Subsequently, in 1998, the FDA declared LMW iron dextran “medically necessary” despite the widespread availability of the HMW product. The FDA definition of medically necessary is, “… if the product is used to treat or prevent a serious medical condition, and there is no other source of that product or alternative drug that is judged by medical staff to be an adequate substitute.” Today, other parenteral iron products are also relatively safer, including ferric gluconate and iron sucrose, although more expensive. In the first study to demonstrate the benefits of intravenous iron when used in conjunction with ESAs for chemotherapy-induced anemia, 79 patients received LMW iron dextran and two patients received HMW iron dextran.9 Although none of the 79 patients receiving LMW iron dextran experienced a serious adverse drug event, one of the two patients who received HMW iron dextran experienced anaphylaxis requiring intubation. Using data from the FDA MedWatch program, Chertow et al.3 determined that the rates of all, as well as life-threatening, adverse drug events were significantly higher among recipients of HMW versus LMW iron dextran or other nondextran iron products. Moreover, using conservative assumptions about the distribution of “iron dextran-associated” adverse drug events where product was not specified, the authors suggest the higher event rate observed with HMW iron dextran may be an underestimate. There also are two published studies in hemodialysis patients comparing LMW iron dextran to iron sucrose,10,11 generally considered by nephrologists to be safer than iron dextran, showing some10 or no difference in toxicity.11 In 2006, different J-codes, which are drug-specific codes used to bill CMS, were assigned to Dexferrum (HMW) and INFeD (LMW) iron dextrans. Providing different J-codes forced providers to discriminate between these products and allowed better tracking of drug-specific adverse reactions. In January 2008, CMS re-merged the J-codes for HMW and LMW iron dextran. For the majority of U.S. physicians who are unaware that two iron dextrans even exist, there is high likelihood that the lower-priced HMW ir

Overview

Integrity signals

Registry

Crossref · 10.1681/asn.2008030255

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

See all 56

Metadata

Authors
Rodgers, G. M., Auerbach, M., Cella, D., Chertow, G. M., Coyne, D. W., Glaspy, J. A., & Henry, D. H.
Affiliations
  • University of Utah (US)
  • Georgetown University (US)
  • Northwestern University (US)
  • Stanford University (US)
  • Washington University in St. Louis (US)
  • University of California, Los Angeles (US)
Corresponding author
  • Rodgers, George M.
  • Henry, David H.
Venue
Journal of the American Society of Nephrology
Published
2008-05
Volume
19
Issue
5
Pages
833-834
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2109124986
Cited by
56
References
32
Citations by year
2025: 1 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 5 · 2013: 3 · 2012: 10
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of the American Society of Nephrology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Hematology › Blood transfusion and management
Keywords
parenteral iron, drug substitution, adverse drug reactions, anaphylaxis, iron deficiency anemia, erythropoiesis-stimulating agents, formulary decisions, iron sucrose, ferric gluconate
MeSH terms
Anaphylaxis, Chemistry, Pharmaceutical, Hematinics, Humans, Iron-Dextran Complex, Molecular Weight, Drug Costs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing? https://app.cochat.ai/papers/10.1681/asn.2008030255
The paper
Rodgers, G. M., Auerbach, M., Cella, D., Chertow, G. M., Coyne, D. W., Glaspy, J. A., & Henry, D. H. (2008). High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing? Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2008030255

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.